Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2013 | 60 | 1 |

Tytuł artykułu

In vitro effect of pentoxifylline and lysefylline on deformability and aggregation of red blood cells from healthy subject and patients with chronic venous disease

Warianty tytułu

Języki publikacji



Purpose. The aim of the study was to assess the in vitro potency of pentoxifylline (PTX) and one of its most active metabolites lisofylline (LSF) to improve rheological properties of red blood cells (RBC) from healthy individuals and patients with chronic venous disease (CVD). Additionally, the study aimed to compare the effects of PTX and LSF on RBC deformability and aggregation. Methods. Blood samples were collected from healthy volunteers (antecubital vein) and from CVD patients (varicose and antecubital vein). Deformability and aggregation of RBC were assessed using Laser-assisted Optical Rotational Cell Analyser (LORCA). Results. PTX and LSF increased RBC elongation significantly. Additionally, RBC incubation with PTX resulted in a marked decrease in RBC aggregation. PTX reduced the tendency towards the formation of RBC aggregates and of their stability. The beneficial effect of PTX on RBC aggregation was most apparent for those cells whose aggregation tendency and aggregate stability was the greatest. Conclusions. In vitro addition of PTX or LSF effectively increased deformability of RBC from healthy donors and patients with CVD. Thus, LSF may contribute to the in vivo hemorheological effects of pentoxifylline. On the other hand, there was no significant effect of LSF on aggregation of RBC in vitro. Hence, LSF has no contribution to this particular effect of PTX. Additionally, the present study demonstrated the use of RBC with impaired deformability and aggregation for the evaluation of in vitro rheological activity of xenobiotics.

Słowa kluczowe








Opis fizyczny



  • Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Cracow, Poland
  • 5th Military Hospital with Polyclinic, Cracow, Poland;
  • 3Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Cracow, Poland
  • Department of Clinical Rehabilitation, University School of Physical Education, Cracow, Poland
  • Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Cracow, Poland


  • Accetto B (1982) Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator-nylidrin. Am Heart J 103: 864-869. 
  • Ambrus JL, Stadler S, Kulaylat M (1995) Hemorrheologic effects of metabolites of pentoxifylline (Trental). J Med 26: 65-75. 
  • Angelkort B, Kiesewetter H (1981) Influence of risk factors and coagulation on the fluidity of blood in chronic arterial occlusive disease. Scand J Clin Lab Invest Suppl 156: 185-188. 
  • Aviado DM, Dettelbach HR (1984) Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology 35: 407-417. 
  • Baskurt OK, Boynard M, Cokelet GC, Connes P, Cooke BM, Forconi S, Liao F, Hardeman MR, Jung F, Meiselman HJ, Nash G, Nemeth N, Neu B, Sandhagen B, Shin S, Thurston G, Wautier JL, International Expert Panel for Standardization of Hemorheological Methods (2009) New guidelines for hemorheological laboratory techniques. Clin Hemorheol Microcirc 42: 75-97. 
  • Beermann B, Ings R, Mansby J, Chamberlain J, McDonald A (1985) Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 37: 25-28. 
  • Boisseau MR, de La Giclais B (2004) Chronic venous diseases: roles of various pathophysiological factors. Clin Hemorheol Microcirc 31: 67-74. 
  • Chwała M, Spannbauer A, Teległów A, Cencora A, Marchewka A, Hardeman MR, Dabrowski Z (2009) Red blood cell rheology in patients with chronic venous disease (CVD). Clin Hemorheol Microcirc 41: 189-195. 
  • Cummings DM, Ballas SK (1990) Effects of pentoxifylline and metabolite on red blood cell deformability as measured by ektacytometry. Angiology 41: 118-123. 
  • Dintenfass L (1983) Action of drugs on the aggregation and deformability of red cells: effect of ABO blood groups. Ann N Y Acad Sci 416: 611-632. 
  • Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DV Jr (2002) Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology 53: 509-520. 
  • Ehrly AM (1979) The effect of pentoxifylline on the deformability of erythrocytes and on the muscular oxygen pressure in patients with chronic arterial disease. J Med 10: 331-338. 
  • Eun BL, Liu XH, Barks JD (2000) Pentoxifylline attenuates hypoxic-ischemic brain injury in immature rats. Pediatr Res 47: 73-78. 
  • Frampton JE, Brogden RN (1995) Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 7: 480-503. 
  • Hardeman MR, Goedhart PT, Dobbe JG, Lettinga KP (1994) Laser assisted Optical Rotational Cell Analyser (LORCA). A new instrument for measurement of various structural hemorheological parameters. Clin Hemorheol 14: 605-618.
  • Hardeman MR, Ince C (1999) Clinical potential of in vitro measured red cell deformability, a myth? Clin Hemorheol Microcirc 21: 277-284. 
  • Hardeman MR, Dobbe JG, Ince C (2001) The Laser-assisted Optical Rotational Cell Analyzer (LORCA) as red blood cell aggregometer. Clin Hemorheol Microcirc 25: 1-11. 
  • Ings RM, Nüdemberg F, Burrows JL, Bryce TA (1982) The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. Eur J Clin Pharmacol 23: 539-543. 
  • Jull A, Waters J, Arroll B (2002) Pentoxifylline for treatment of venous leg ulcers: a systematic review. Lancet 359: 1550-1554. 
  • Leonhardt H, Grigoleit HG (1977) Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions. Naunyn Schmiedebergs Arch Pharmacol 299: 197-200. 
  • Lipovac V, Gavella M, Vucić M, Mrzljak V, Rocić B (2000) Effect of creatine on erythrocyte rheology in vitro. Clin Hemorheol Microcirc 22: 45-52. 
  • Marton Z, Kesmarky G, Vekasi J, Cser A, Russai R, Horvath B, Toth K (2001) Red blood cell aggregation measurements in whole blood and in fibrinogen solutions by different methods. Clin Hemorheol Microcirc 24: 75-83. 
  • Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG (2000) Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 59: 1057-1070. 
  • Muller R (1981) Hemorheology and peripheral vascular diseases: A new therapeutic approach. J Med 12: 209-235. 
  • Muravyov AV, Yakusevich VV, Chuchkanov FA, Maimistova AA, Bulaeva SV, Zaitsev LG (2007) Hemorheological efficiency of drugs, targeting on intracellular phosphodiesterase activity: in vitro study. Clin Hemorheol Microcirc 36: 327-334. 
  • Nakao M, Nakao T, Yamazoe S (1960) Adenosine triphosphate and maintenance of shape of the human red cells. Nature 187: 945-946. 
  • Nicklasson M, Björkman S, Roth B, Jönsson M, Höglund P (2002) Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 14: 643-652. 
  • Ott E, Lechner H, Fazekas F (1983) Hemorheological effects of pentoxifylline in disturbed blood flow behaviour in patients with cerebrovascular disease. Eur Neurol 22 (Suppl 1): 105-107. 
  • Perego MA, Sergio G, Artale F (1983) Hemorheological aspect of the pathophysiology and clinical features of peripheral occlusive arterial disease. Pharmatherapeutica 3 (Suppl 1): 91-101.
  • Pękala E, Godawska-Matysik A, Żelaszczyk D (2007) Enantioselective reduction of pentoxifylline to lisofylline using whole cell Lactobacillus kefiri biotransformation. Biotechnol J 2: 492-496. 
  • Schneider R (1989) Results of hemorheologically active treatment with pentoxifylline in patients with cerebrovascular disease. Angiology 40: 987-993. 
  • Salbaş K, Gürlek A, Akyol T (1994) In vitro effect of nicotine on red blood cell deformability in untreated and treated essential hypertension. Scand J Clin Lab Invest 54: 659-663. 
  • Seiffge D, Kiesewetter H (1981) Effect of pentoxifylline on single red cell deformability. Klin Wochenschr 59: 1271-1272. 
  • Seiffge D (1982) Effect of pentoxifylline on red cell aggregation. IRCS Med Sci 8: 727-734.
  • Singh M, Kumaravel M (1996) Influence of pentoxifylline and dispirin on aggregation and deformability of erythrocytes under in vitro conditions. Indian J Biochem Biophys 33: 199-205. 
  • Skalak R, Zarda PR, Jan KM, Chien S (1981) Mechanics of rouleau formation. Biophys J 35: 771-781. 
  • Stefanovich V (1975) Effect of pentoxifylline on energy rich phosphates in rat's erythrocytes. Res Commun Chem Pathol Pharmacol 10: 747-750. 


rekord w opracowaniu

Typ dokumentu



Identyfikator YADDA

JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.